Cleveland Clinic researchers have launched the next step in their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
An analysis led by Brown University researchers showed that work shift is an important factor to consider when designing workplace health interventions.
People who know someone who became ill with COVID-19 or died from the disease are twice as likely to receive a COVID-19 vaccine, according to a study led by Rutgers and Penn State University.
Few studies have evaluated the waning of vaccine effectiveness against severe outcomes caused by SARS-CoV-2 Omicron infection. Hong Kong is providing inactivated and mRNA vaccines, but the population had limited protection from natural infections before the Omicron variant emerged.
Breakthrough COVID-19 infections after vaccination occurred in 7.5% of Texans surveyed and higher odds were associated with Hispanic ethnicity, larger household size, rural versus urban living, type of vaccination, and multiple comorbidities, according to findings from UTHealth Houston School of Public Health published today in the Journal of Infectious Diseases.
Pia Pannaraj, MD, MPH, an infectious disease specialist at Children's Hospital Los Angeles, was awarded $4.2 million from the National Institutes of Health to study COVID-19 immunity in children.
Implementing financial coaching for parents of infants in a pediatric primary care setting reduced missed well-child care visit rates by half and significantly improved receipt of vaccinations at a timely age, according to a new community-partnered pilot study led by UCLA researchers.
The Cotswold Foundation Postdoctoral Fellowship is a new fellowship totaling $500,000 over the course of five years to support a postdoctoral researcher studying immunology, cancer research, or vaccine biology at The Wistar Institute.
Not for public release
This news release is embargoed until 30-Jan-2023 5:00 PM EST
Released to reporters: 24-Jan-2023 2:20 PM EST
A reporter's PressPass is required to
access this story until the embargo expires on 30-Jan-2023 5:00 PM EST
The Newswise PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
A booster (third) dose of a SARS-CoV-2 vaccine was associated with a 90% reduction in death in people with multiple health conditions compared to 2 doses, according to a new study from Hong Kong published in CMAJ (Canadian Medical Association Journal).
The main point of the study, which was completed before other variants came on the scene, is for pregnant women to get vaccinated and receive all their boosters, including the bivalent booster.
Three years ago this month, the first case of COVID was diagnosed in the United States. Here are the latest figures on the pandemic, collected by UCLA Health hospitals and clinics.
Las vacunas han protegido a las personas de enfermedades mortales durante generaciones. ¿También podrían ayudar a combatir el cáncer? Los investigadores de Mayo Clinic están trabajando en el desarrollo de vacunas terapéuticas personalizadas contra el cáncer que podrían atacar las características distintivas de los tumores en cada persona.
As vacinas protegem as pessoas contra doenças mortais ao longo de gerações, mas será que elas também poderiam ajudar a combater o câncer? Os pesquisadores da Mayo Clinic estão trabalhando para desenvolver vacinas terapêuticas personalizadas contra o câncer.
As its 11th-anniversary approaches, the National Primate Research Center of Thailand Chulalongkorn University (NPRCT-CU) and the Primates Enterprise Co., Ltd. are pleased to announce two events in February 2023:
جاكسونفيل، فلوريدا — لطالما حمت اللقاحات الناس من الأمراض الفتاكة لأجيال. فهل يمكنها أيضًا المساعدة في محاربة السرطان؟ يعمل باحثو مايو كلينك على تطوير لقاحات علاجية مخصصة للسرطان يمكنها استهداف خصائص الورم المميزة لكل شخص. إن هذا النهج الجديد، المبني على التقدم في الأبحاث الجينومية وتحليلات البيانات، يحمل إمكانات تحويلية لتعزيز قوة الجهاز المناعي للتعرف على الخلايا السرطانية ومهاجمتها.
A new COVID-19 vaccine based on a different platform than current vaccines on the market has been tested in humans for the first time by researchers at Radboud university medical center.
For the first time, researchers at UC San Diego have created an atomic-level computer model of the H1N1 virus that reveals new vulnerabilities, suggesting possible strategies for the design of future vaccines and antivirals against influenza.
The Wistar Institute, which has recently launched a $75 million programmatic campaign investing in biomedical advances, announces the appointment of Michael Criscuolo as Vice President of Development.
The federally funded COVID-19 Prevention Network was instrumental in the rapid development of safe, effective and lifesaving COVID-19 vaccines during earlier phases of the pandemic. This vital work to expedite Phase 3 clinical trials also resulted in a 'treasure trove' of data, thanks to a highly collaborative and harmonized approach that can serve as a national and even international model for major research initiatives while also guiding responses to future public health emergencies.
Using prenatal magnetic resonance imaging, a group of MedUni Vienna researchers examined the placentas and foetuses of women who tested positive for SARS-CoV-2 during pregnancy.
Nearly half a million people missed out on starting medication to lower their blood pressure during the Covid-19 pandemic, according to research supported by the British Heart Foundation (BHF) Data Science Centre at Health Data Research UK published today in Nature Medicine [1].
In this study of 1,832 U.S. adults, the risk of reporting symptoms for 28 or more days after COVID-19 onset was significantly higher in participants who were unvaccinated at the time of infection and those who reported moderate or severe acute illness symptoms.
If pharmaceutical companies shared their intellectual property rights to vaccines with the global community, millions of lives could be saved in future pandemics, according to a new paper co-authored by faculty at Binghamton University, State University of New York.
The global network led by the Oxford Maternal and Perinatal Health Institute (OMPHI) at the University of Oxford has published in the journal Lancet the results of the ‘2022 INTERCOVID Study’ conducted in 41 hospitals across 18 countries, including Ann & Robert H. Lurie Children’s Hospital of Chicago.
A Phase 3 study of an investigational HIV vaccine regimen has been discontinued following a planned, interim review by the study’s independent Data and Safety Monitoring Board. The investigational vaccine was generally safe and well tolerated; however, it was not effective at preventing the acquisition of HIV-1. The results of the uniquely designed and implemented Mosaico study underscore the challenges that have faced the global scientific community in the 40-year search for an HIV vaccine, and may provide important data in the ongoing fight against HIV.
Just as a highly transmissible variant prompts officials to extend COVID-19 emergency status, one of the largest surveys ever conducted shows people are more willing to get vaccinated when health workers reveal how many others are doing so.
High levels of mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months. Omicron infection generates durable mucosal antibodies, reducing the risk of re-infection.
NEW YORK, NY – Jan. 17, 2023 – The American Thoracic Society is starting the new year poised to improve vaccination rates with three health system partners: University of Arizona/ Banner Health; West Virginia University Hospitals, Inc.; and San Francisco Health Network/ University of California.
Results of the 18-month study, published in Lancet Regional Health - Americas and led by Amit Bahl, M.D., M.P.H., emergency medicine with Corewell Health East, formerly Beaumont Health, showed that while omicron cases had the highest hospital admission rates among children ages 0 to 17, serious, even deadly, cases of illness were less likely during omicron than during the delta and alpha variants. In fact, the odds of severe disease were 65% lower during omicron compared to alpha.
Findings from a newly published study provide further evidence suggesting that the breast milk of those vaccinated against COVID-19 may help protect babies from the illness
While COVID-19 boosters have been found to protect against infection, hospitalization, and severe illness, the waning of their protection has led to uncertainty about when it is most appropriate to get an additional booster shot.
A team of researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen has gained new insights into the maturation of SARS-CoV-specific antibodies after multiple vaccinations with the mRNA vaccine Comirnaty.
A belief that COVID-19 was a myth created to control ethnic populations, or a virus created to eliminate the Black community were among the conspiracy theories that caused a lower engagement of health prevention methods among UK Black communities, research by Kingston University, London experts has shown.
Hepatitis B virus (HBV) infections remain a major global health problem – according to the World Health Organization (WHO) there are around 300 million HBV carriers worldwide. Current treatments rarely succeed in curing the infection.
A new analysis by Cedars-Sinai investigators is furthering the scientific community’s understanding of COVID-19 immunity by showing that similar levels of COVID-19 antibodies are reached over an extended period of time in different population groups.
With a return to the workplace and school, the UK Health Security Agency recently warned that cases of flu and COVID-19 are expected to soar throughout January.
Researchers at Washington University School of Medicine in St. Louis have discovered that vaccinating mice against a toxin produced by the bacterium E. coli can prevent intestinal damage, a finding that suggests new ways to prevent malnutrition and stunting in children.
Global willingness to accept a COVID-19 vaccine increased from 75.2% in 2021 to 79.1% in 2022, according to a new survey of 23 countries that represent more than 60% of the world’s population, published today in Nature Medicine.
Christian Bréchot, MD, PhD, President of the Global Virus Network (GVN), Associate Vice President for International Partnerships and Innovation at the University of South Florida and Professor of the Division of Infectious Disease, Department of Internal Medicine at USF Health Morsani College of Medicine, the GVN Southeast U.S. Regional Headquarters today issued a statement on the surge of SARS-CoV-2.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. Interested in news you may have missed in 2022 from Fred Hutch?
A new study led by Luís Graça, group leader at the Instituto de Medicina Molecular João Lobo Antunes (iMM, Lisbon) and full professor at the Medical School of the University of Lisbon, and Manuel Carmo Gomes, associate professor with aggregation at the Faculty of Sciences of the University of Lisbon (Ciências ULisboa), both members of the Direção Geral de Saúde (DGS) Technical Committee for Vaccination against COVID-19 (CTVC), and published today in the scientific journal Lancet Infectious Diseases*, shows that the protection conferred by hybrid immunity against the SARS-CoV-2 subvariant omicron BA.5, obtained by the infection of vaccinated people, lasts for at least eight months after the first infection.
The long-term effects of infection on the immune system have long intrigued John Tsang, a Yale immunobiologist. After the body has faced down a pathogen, does the immune system return to the previous baseline? Or does a single infection change it in ways that alter how it will respond not only to a familiar virus but also to the next new viral or bacterial threat it faces?
A three-dose regimen of a whole-parasite vaccine against malaria – called Plasmodium falciparum sporozoite (PfSPZ) vaccine – demonstrated safety and efficacy when tested in adults living in Burkina Faso, West Africa, which has endemic malaria.